Fostamatinib – Uses, Dosage, Side Effects, Interaction Fostamatinib is an orally available small-molecule inhibitor of spleen tyrosine kinase that is used to treat chronic immune thrombocytopenia. Fostamatinib is associated with transient and usually mild elevations in serum aminotransferase levels during therapy but has yet to be linked to instances of clinically apparent acute liver injury. Fostamatinib is a small molecule Syk kinase inhibitor with potential anti-inflammatory and immunomodulating activities. Fostamatinib inhibits Syk kinase-mediated IgG Fc gamma receptor signaling, resulting in the inhibition of the activation of mast cells, macrophages, and B-cells and related inflammatory responses and tissue damage. Syk kinase, widely expressed in hematopoietic cells, is a nonreceptor tyrosine kinase that is involved in coupling activated immunoreceptors to signal downstream events that mediate diverse cellular responses, including proliferation, differentiation, and phagocytosis. Fostamatinib Disodium is an orally available disodium salt of the Syk kinase inhibitor fostamatinib with potential anti-inflammatory and immunomodulating activities. Fostamatinib inhibits Syk kinase-mediated IgG Fc gamma receptor signaling, resulting in the inhibition of the activation of mast cells, macrophages, and B-cells and related inflammatory responses and tissue damage. Syk kinase, widely expressed in hematopoietic cells, is a nonreceptor tyrosine kinase that is involved in coupling activated immunoreceptors to signal downstream events that mediate diverse cellular responses, including proliferation, differentiation, and phagocytosis. Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP. Fostamatinib has also been granted orphan drug status by the FDA. Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK kinase. Mechanism of Action The active metabolite of fostamatinib, R406, is an inhibitor of spleen tyrosine kinase (Syk). It binds reversibly to the ATP binding pocket with high affinity (Ki = 30nM), inhibiting the kinase activity with an IC50 of 41nM. Syk is a cytosolic protein kinase and part of the signaling cascade which occurs with Fc receptors, TCRs, and BCRs. It contains two src homology 2 (SH2) domains separated by a linker domain. These SH2 domains bind to tyrosine residues on the immunoreceptor tyrosine-based activating motif phosphorylated by Lyn, another kinase in the cascade. This motif is located on the cytoplasmic regions of several immune receptors including Fc receptors, TCRs, BCRs, and natural killer cell receptors. The flexibility provided by the linker enables the protein to bind to many receptor types. Inhibition of Syk suppresses downstream signal transduction. While Syk plays a role in some pathways involved in the generation of the oxidative burst by neutrophils or phagocytosis by macrophages, R406 does not have a significant effect on these processes. This is likely due to redundant pathways which do not involve Syk. Similarly, Syk does not produce significant effects on platelet activation despite its involvement in glycoprotein IV and integrin-based signaling. Activation of antibody-dependent cell-mediated toxicity by natural killer cells is also unaffected despite the involvement of Syk in Fc receptor signaling. R406 binds to the adenosine A3 receptor as an antagonist as well as the adenosine and monoamine uptake transporters as an inhibitor. It has also been found to be an inhibitor of UDP glucuronosyltransferase UGT1A1, phosphodiesterase PDE5, fatty acid amide hydrolase, 5-lipoxygenase, cathepsin L, and cathepsin S. R406 appears to inhibit a wide range of kinases at higher concentrations. It is thought that inhibition of some of these targets may be responsible for the increase in blood pressure seen with fostamatinib. The active metabolite of fostamatinib, R406, inhibits signal transduction by Fcγ receptors involved in the antibody-mediated destruction of platelets by immune cells in chronic ITP. This results in increased platelet counts in this population. R406 produces inhibition of T and B lymphocyte activation by T-cell receptors (TCRs) and B-cell receptors (BCRs) respectively. It can also inhibit signaling via Fcε receptors which could have applications in treating allergic symptoms through the prevention of mast cell degranulation. Inhibition of Fc receptor signaling system also affected by R406 suppresses both dendritic cell maturation and antigen presentation and may contribute to the effects of fostamatinib. As a knock-on effect of disabling signal transduction from Fc receptors, TCRs, and BCRs, the production of inflammatory mediators and cytokines like tumor necrosis factor α, leukotriene C4, interleukin-8, and granulocyte-macrophage colony-stimulating factor. Fostamatinib can produce hypertension through off-target effects Indications Fostamatinib is indicated for use in the treatment of chronic immune thrombocytopenia (ITP) in patients who have had an insufficient response to previous therapy. Tables are indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments. Fostamatinib is a spleen tyrosine kinase inhibitor used to treat chronic immune thrombocytopenia after attempting one other treatment. Treatment of idiopathic thrombocytopenic purpura as a model for immunomodulation Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylarthritis, psoriatic arthritis,. and juvenile idiopathic arthritis ) Fostamatinib is an orally available small-molecule inhibitor of spleen tyrosine kinase that is used to treat chronic immune thrombocytopenia. For the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK kinase. Chronic immune thrombocytopenia Contraindications low levels of a type of white blood cell called neutrophils high blood pressure liver problems diarrhea pregnancy a patient who is producing milk and breastfeeding a significant drop in a certain type of white blood cell called a neutrophil Dosage Strengths: 100 mg; 150 mg Thrombocytopenia 100 mg orally 2 times a day; after a month, if platelet count has not increased to at least 50 x 10(9)/L, increase to 150 mg orally 2 times a day This drug may be taken with or without food. In the case of a missed dose, instruct patients to take their next dose at its regularly scheduled time. Use the lowest dose to achieve and maintain a platelet count at least 50 x 10(9)/L to reduce the risk of bleeding. Dose Adjustments Dose modification is recommended based on individual safety and tolerability. Management of some adverse reactions may require dose interruption, reduction, or discontinuation. MANUFACTURER SUGGESTED DOSE REDUCTION SCHEDULE: 300 mg/day: Taken as 150 mg orally in the AM and 150 mg orally in the PM 200 mg/day: Taken as 100 mg orally in the AM and 100 mg orally in the PM 150 mg/day: Taken as 150 mg orally in the AM 100 mg/day: Taken as 100 mg orally in the AM If further dose reduction is needed, therapy should be discontinued. RECOMMENDED DOSE MODIFICATIONS FOR SPECIFIC ADVERSE REACTIONS: HYPERTENSION: Stage 1 (systolic between 130 and 139 or diastolic between 80 and 89 mmHg: Initiate or increase dose of antihypertensive medication for patients with increased cardiovascular risk, and adjust as needed until BP is controlled. If the BP target is not met after 8 weeks, reduce the dose to the next lower daily dose. Stage 2 (systolic at least 140 or diastolic at least 90 mmHg: Initiate or increase dose of antihypertensive medication, and adjust as needed until BP is controlled. If the BP remains 140/90 mmHg or higher for more than 8 weeks, reduce the dose to the next lower daily dose. If BP remains 160/100 mmHg or higher for more than 4 weeks despite aggressive antihypertensive therapy, interrupt or discontinue therapy. HEPATOTOXICITY: AST/ALT is 3 x ULN or higher and less than 5 x ULN: If the patient is symptomatic (e.g., nausea, vomiting, abdominal pain), interrupt therapy; recheck LFTs every 72 hours until ALT/AST values are no longer elevated (below 1.5 x ULN) and total bilirubin (BL) remains less than 2 x ULN; resume therapy at next lower daily dose. If the patient is asymptomatic, recheck LFTs every 72 hours until ALT/AST are below 1.5 x ULN and total BL remains less than 2 x ULN; consider therapy interruption or dose reduction if ALT/AST and TBL remain in this category (AST/ALT is 3 to 5 x ULN; and total BL remains less than 2 x ULN); if therapy is interrupted, resume at the next lower daily dose when ALT/AST are no longer elevated (below 1.5 x ULN) and total BL remains less than 2 x ULN. AST/ALT is 5 x ULN or higher and total BL is less than 2 x ULN: Interrupt therapy and recheck LFTs every 72 hours; if AST and ALT decrease, recheck until ALT and AST are no longer elevated (below 1.5 x ULN) and total BL remains less than 2 x ULN; resume therapy at next lower daily dose; if AST/ALT persist at 5 x ULN or higher for 2 weeks or more, discontinue therapy. AST/ALT is 3 x ULN or higher and total BL is greater than 2 x ULN: Discontinue therapy. Elevated unconjugated (indirect) BL in absence of other LFT abnormalities: Continue therapy with frequent monitoring since the isolated increase in unconjugated (indirect) BL may be due to UGT1A1 inhibition. DIARRHEA: Manage diarrhea using supportive measures (e.g., dietary changes, hydration, and/or antidiarrheal medication) early after the onset until symptoms have resolved. If symptom(s) become severe (Grade 3 or above), temporarily interrupt therapy. If diarrhea improves to mild (Grade 1), resume therapy at the next lower daily dose. NEUTROPENIA: If absolute neutrophil count decreases (ANC less than 1 x 10(9)/L) and remains low after 72 hours, temporarily interrupt therapy until resolved (ANC greater than 1.5 x 10(9)/L). Resume therapy at the next lower daily dose. DOSE MODIFICATION FOR DRUG INTERACTIONS Concomitant use with a strong CYP450 3A4 inhibitor increases exposure to R406 (the major active metabolite). Monitor for toxicities due to this drug that may require dose modifications when given concurrently with a strong CYP450 3A4 inhibitor. DISCONTINUATION OF THERAPY: Discontinue therapy after 12 weeks if the platelet count does not increase to a level sufficient to avoid clinically important bleeding. Administration advice: This drug may be taken with or without food. In case of a missed dose, the next dose should be taken at its regularly scheduled time. Side Effects The Most Common diarrhea nausea dizziness rash abdominal pain fatigue severe diarrhea headache, confusion, dizziness, chest pain, or shortness of breath pain in the upper right part of the stomach yellowing of the skin or eyes dark colored urine nausea vomiting More common Black, tarry, stools blurred vision chest pain chills cough diarrhea dizziness fever headache lower back or side pain nervousness painful or difficult urination pale skin pounding in the ears slow or fast heartbeat sore throat stomach pain ulcers, sores, or white spots in the mouth unusual bleeding or bruising unusual tiredness or weakness Rare severe diarrhea; stomach pain (upper right side); dark urine, jaundice (yellowing of the skin or eyes); headaches, chest pain, shortness of breath; or fever, sore throat, or other signs of infection. increased blood pressure; diarrhea, nausea, stomach pain; abnormal liver function tests; chest pain; dizziness, tiredness; rash; or cold symptoms such as stuffy nose, sneezing, and sore throat. Drug Interactions DRUG INTERACTION Abacavir The metabolism of Abacavir can be decreased when combined with Fostamatinib. Abaloparatide The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Fostamatinib. Abametapir The serum concentration of Fostamatinib can be increased when it is combined with Abametapir. Abemaciclib The metabolism of Abemaciclib can be decreased when combined with Fostamatinib. Acalabrutinib The metabolism of Acalabrutinib can be decreased when combined with Fostamatinib. Acebutolol Fostamatinib may increase the antihypertensive activities of Acebutolol. Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Fostamatinib. Acetaminophen The serum concentration of Acetaminophen can be increased when it is combined with Fostamatinib. Afatinib Fostamatinib may decrease the excretion rate of Afatinib which could result in a higher serum level. Albendazole The metabolism of Albendazole can be decreased when combined with Fostamatinib. Aldesleukin The risk or severity of hypotension can be increased when Fostamatinib is combined with Aldesleukin. Alectinib The metabolism of Alectinib can be decreased when combined with Fostamatinib. Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Fostamatinib. Aliskiren Fostamatinib may increase the antihypertensive activities of Aliskiren. Allopurinol Fostamatinib may decrease the excretion rate of Allopurinol which could result in a higher serum level. Alpelisib The serum concentration of Alpelisib can be increased when it is combined with Fostamatinib. Alprazolam The metabolism of Alprazolam can be decreased when combined with Fostamatinib. Alprostadil The risk or severity of hypotension and priapism can be increased when Fostamatinib is combined with Alprostadil. Ambrisentan Fostamatinib may increase the antihypertensive activities of Ambrisentan. Amifostine The risk or severity of hypotension can be increased when Fostamatinib is combined with Amifostine. Amiloride The risk or severity of hypotension can be increased when Fostamatinib is combined with Amiloride. Aminophylline The metabolism of Aminophylline can be decreased when combined with Fostamatinib. Amiodarone The metabolism of Fostamatinib can be decreased when combined with Amiodarone. Amitriptyline The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Amitriptyline. Amlodipine Fostamatinib may increase the antihypertensive activities of Amlodipine. Amoxapine The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Amoxapine. Amphotericin B The risk or severity of hypotension can be increased when Fostamatinib is combined with Amphotericin B. Amprenavir The metabolism of Fostamatinib can be decreased when combined with Amprenavir. Amyl Nitrite The risk or severity of hypotension can be increased when Fostamatinib is combined with Amyl Nitrite. Apalutamide The metabolism of Fostamatinib can be increased when combined with Apalutamide. Apixaban Fostamatinib may decrease the excretion rate of Apixaban which could result in a higher serum level. Apomorphine The risk or severity of hypotension can be increased when Fostamatinib is combined with Apomorphine. Apraclonidine The risk or severity of hypotension can be increased when Fostamatinib is combined with Apraclonidine. Aprepitant The metabolism of Fostamatinib can be decreased when combined with Aprepitant. Aripiprazole The metabolism of Aripiprazole can be decreased when combined with Fostamatinib. Aripiprazole lauroxil The metabolism of Aripiprazole lauroxil can be decreased when combined with Fostamatinib. Arsenic trioxide The risk or severity of hypotension can be increased when Fostamatinib is combined with Arsenic trioxide. Asenapine The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Asenapine. Astemizole The metabolism of Astemizole can be decreased when combined with Fostamatinib. Atazanavir The metabolism of Fostamatinib can be decreased when combined with Atazanavir. Atenolol Fostamatinib may increase the antihypertensive activities of Atenolol. Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Fostamatinib. Avanafil The serum concentration of Avanafil can be increased when it is combined with Fostamatinib. Axitinib The metabolism of Axitinib can be decreased when combined with Fostamatinib. Azilsartan medoxomil Fostamatinib may increase the antihypertensive activities of Azilsartan medoxomil. Azithromycin The metabolism of Azithromycin can be decreased when combined with Fostamatinib. Bazedoxifene The metabolism of Bazedoxifene can be decreased when combined with Fostamatinib. Belinostat The metabolism of Belinostat can be decreased when combined with Fostamatinib. Benazepril Fostamatinib may increase the antihypertensive activities of Benazepril. Bendroflumethiazide Fostamatinib may increase the antihypertensive activities of Bendroflumethiazide. Bepridil Fostamatinib may increase the antihypertensive activities of Bepridil. Berotralstat The serum concentration of Berotralstat can be increased when it is combined with Fostamatinib. Betaxolol Fostamatinib may increase the antihypertensive activities of Betaxolol. Bethanidine Fostamatinib may increase the antihypertensive activities of Bethanidine. Bicalutamide The metabolism of Bicalutamide can be decreased when combined with Fostamatinib. Bictegravir The metabolism of Bictegravir can be decreased when combined with Fostamatinib. Binimetinib The metabolism of Binimetinib can be decreased when combined with Fostamatinib. Bisoprolol Fostamatinib may increase the antihypertensive activities of Bisoprolol. Boceprevir The metabolism of Fostamatinib can be decreased when combined with Boceprevir. Bortezomib The metabolism of Bortezomib can be decreased when combined with Fostamatinib. Bosentan Fostamatinib may increase the antihypertensive activities of Bosentan. Bosutinib The metabolism of Bosutinib can be decreased when combined with Fostamatinib. Brentuximab vedotin The metabolism of Brentuximab vedotin can be decreased when combined with Fostamatinib. Bretylium Fostamatinib may increase the antihypertensive activities of Bretylium. Brexpiprazole The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Brexpiprazole. Brigatinib The metabolism of Brigatinib can be decreased when combined with Fostamatinib. Brimonidine The risk or severity of hypotension can be increased when Fostamatinib is combined with Brimonidine. Bromocriptine The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Bromocriptine. Bumetanide The risk or severity of hypotension can be increased when Fostamatinib is combined with Bumetanide. Bupivacaine The risk or severity of hypotension can be increased when Fostamatinib is combined with Bupivacaine. Buprenorphine The metabolism of Buprenorphine can be decreased when combined with Fostamatinib. Busulfan The metabolism of Busulfan can be decreased when combined with Fostamatinib. Cabazitaxel The metabolism of Cabazitaxel can be decreased when combined with Fostamatinib. Cabergoline The metabolism of Cabergoline can be decreased when combined with Fostamatinib. Cabotegravir The metabolism of Cabotegravir can be decreased when combined with Fostamatinib. Canagliflozin The risk or severity of hypotension can be increased when Fostamatinib is combined with Canagliflozin. Candesartan cilexetil Fostamatinib may increase the antihypertensive activities of Candesartan cilexetil. Cannabidiol The metabolism of Fostamatinib can be decreased when combined with Cannabidiol. Captopril Fostamatinib may increase the antihypertensive activities of Captopril. Carbamazepine The metabolism of Carbamazepine can be decreased when combined with Fostamatinib. Carbetocin The risk or severity of hypotension can be increased when Fostamatinib is combined with Carbetocin. Carbimazole The therapeutic efficacy of Carbimazole can be decreased when used in combination with Fostamatinib. Carteolol The risk or severity of hypotension can be increased when Fostamatinib is combined with Carteolol. Carvedilol The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Carvedilol. Celecoxib Fostamatinib may decrease the excretion rate of Celecoxib which could result in a higher serum level. Celiprolol Fostamatinib may increase the antihypertensive activities of Celiprolol. Cenobamate The serum concentration of Fostamatinib can be decreased when it is combined with Cenobamate. Cephalexin The metabolism of Cephalexin can be decreased when combined with Fostamatinib. Ceritinib The metabolism of Ceritinib can be decreased when combined with Fostamatinib. Cerivastatin Fostamatinib may decrease the excretion rate of Cerivastatin which could result in a higher serum level. Chlorothiazide Fostamatinib may increase the antihypertensive activities of Chlorothiazide. Chlorpromazine The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Chlorpromazine. Chlorthalidone Fostamatinib may increase the antihypertensive activities of Chlorthalidone. Cilazapril Fostamatinib may increase the antihypertensive activities of Cilazapril. Cilostazol The metabolism of Cilostazol can be decreased when combined with Fostamatinib. Ciprofloxacin The metabolism of Fostamatinib can be decreased when combined with Ciprofloxacin. Cisapride The metabolism of Cisapride can be decreased when combined with Fostamatinib. Cladribine Fostamatinib may decrease the excretion rate of Cladribine which could result in a higher serum level. Clarithromycin The metabolism of Fostamatinib can be decreased when combined with Clarithromycin. Clevidipine The risk or severity of hypotension can be increased when Fostamatinib is combined with Clevidipine. You Might Also Read Fibromyalgia, Causes, Symptoms, Diagnosis, Treatment Clofarabine Fostamatinib may decrease the excretion rate of Clofarabine which could result in a higher serum level. Clomipramine The metabolism of Clomipramine can be decreased when combined with Fostamatinib. Clonidine The metabolism of Clonidine can be decreased when combined with Fostamatinib. Clozapine The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Clozapine. Cobicistat The metabolism of Fostamatinib can be decreased when combined with Cobicistat. Cobimetinib The metabolism of Cobimetinib can be decreased when combined with Fostamatinib. Colchicine The metabolism of Colchicine can be decreased when combined with Fostamatinib. Conivaptan The metabolism of Fostamatinib can be decreased when combined with Conivaptan. Conjugated estrogens Fostamatinib may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level. Copanlisib The metabolism of Copanlisib can be decreased when combined with Fostamatinib. Crizotinib The metabolism of Crizotinib can be decreased when combined with Fostamatinib. Cryptenamine Fostamatinib may increase the antihypertensive activities of Cryptenamine. Curcumin The metabolism of Fostamatinib can be decreased when combined with Curcumin. Cyclopenthiazide Fostamatinib may increase the antihypertensive activities of Cyclopenthiazide. Cyclophosphamide The metabolism of Cyclophosphamide can be decreased when combined with Fostamatinib. Cyclosporine The metabolism of Cyclosporine can be decreased when combined with Fostamatinib. Cyclothiazide Fostamatinib may increase the antihypertensive activities of Cyclothiazide. Dabrafenib The serum concentration of Fostamatinib can be decreased when it is combined with Dabrafenib. Dacomitinib The metabolism of Dacomitinib can be decreased when combined with Fostamatinib. Dactinomycin Fostamatinib may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Danazol The metabolism of Fostamatinib can be decreased when combined with Danazol. Dapagliflozin The risk or severity of hypotension can be increased when Fostamatinib is combined with Dapagliflozin. Darolutamide Fostamatinib may decrease the excretion rate of Darolutamide which could result in a higher serum level. Darunavir The metabolism of Fostamatinib can be decreased when combined with Darunavir. Dasatinib The metabolism of Dasatinib can be decreased when combined with Fostamatinib. Dasiglucagon Fostamatinib may increase the antihypertensive activities of Dasiglucagon. Daunorubicin Fostamatinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Debrisoquine Fostamatinib may increase the antihypertensive activities of Debrisoquine. Deferasirox The metabolism of Deferasirox can be decreased when combined with Fostamatinib. Delafloxacin Fostamatinib may decrease the excretion rate of Delafloxacin which could result in a higher serum level. Delavirdine The metabolism of Fostamatinib can be decreased when combined with Delavirdine. Deserpidine Fostamatinib may increase the antihypertensive activities of Deserpidine. Desflurane The risk or severity of hypotension can be increased when Fostamatinib is combined with Desflurane. Desvenlafaxine The metabolism of Fostamatinib can be decreased when combined with Desvenlafaxine. Dexamethasone The metabolism of Fostamatinib can be increased when combined with Dexamethasone. Dexibuprofen The metabolism of Dexibuprofen can be decreased when combined with Fostamatinib. Dexmedetomidine The risk or severity of hypotension can be increased when Fostamatinib is combined with Dexmedetomidine. Diazoxide Fostamatinib may increase the antihypertensive activities of Diazoxide. Diclofenac The metabolism of Diclofenac can be decreased when combined with Fostamatinib. Diclofenamide The risk or severity of hypotension can be increased when Fostamatinib is combined with Diclofenamide. Diflunisal The metabolism of Fostamatinib can be decreased when combined with Diflunisal. Digitoxin The metabolism of Digitoxin can be decreased when combined with Fostamatinib. Dihydralazine Fostamatinib may increase the antihypertensive activities of Dihydralazine. Dihydroergocornine The metabolism of Dihydroergocornine can be decreased when combined with Fostamatinib. Dihydroergocristine The metabolism of Dihydroergocristine can be decreased when combined with Fostamatinib. Dihydroergotamine The metabolism of Dihydroergotamine can be decreased when combined with Fostamatinib. Diltiazem The metabolism of Fostamatinib can be decreased when combined with Diltiazem. Dinutuximab The risk or severity of hypotension can be increased when Fostamatinib is combined with Dinutuximab. Dipyridamole The risk or severity of adverse effects can be increased when Dipyridamole is combined with Fostamatinib. Docetaxel The metabolism of Docetaxel can be decreased when combined with Fostamatinib. Dofetilide The metabolism of Dofetilide can be decreased when combined with Fostamatinib. Dolutegravir Fostamatinib may decrease the excretion rate of Dolutegravir which could result in a higher serum level. Donepezil Fostamatinib may decrease the excretion rate of Donepezil which could result in a higher serum level. Doxazosin The risk or severity of hypotension can be increased when Fostamatinib is combined with Doxazosin. Doxepin The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Doxepin. Doxorubicin The metabolism of Doxorubicin can be decreased when combined with Fostamatinib. Dronabinol The serum concentration of Dronabinol can be increased when it is combined with Fostamatinib. Dronedarone The metabolism of Dronedarone can be decreased when combined with Fostamatinib. Droperidol The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Droperidol. Drospirenone The metabolism of Drospirenone can be decreased when combined with Fostamatinib. Duvelisib Fostamatinib may decrease the excretion rate of Duvelisib which could result in a higher serum level. Ebastine The metabolism of Ebastine can be decreased when combined with Fostamatinib. Efavirenz The metabolism of Fostamatinib can be decreased when combined with Efavirenz. Elagolix The metabolism of Elagolix can be decreased when combined with Fostamatinib. Elexacaftor The metabolism of Elexacaftor can be decreased when combined with Fostamatinib. Eliglustat The metabolism of Eliglustat can be decreased when combined with Fostamatinib. Eltrombopag The metabolism of Eltrombopag can be decreased when combined with Fostamatinib. Elvitegravir The metabolism of Fostamatinib can be decreased when combined with Elvitegravir. Empagliflozin The risk or severity of hypotension can be increased when Fostamatinib is combined with Empagliflozin. Enalapril Fostamatinib may increase the antihypertensive activities of Enalapril. Enalaprilat Fostamatinib may increase the antihypertensive activities of Enalaprilat. Enasidenib The metabolism of Enasidenib can be decreased when combined with Fostamatinib. Entrectinib The metabolism of Entrectinib can be decreased when combined with Fostamatinib. Enzalutamide The serum concentration of Fostamatinib can be decreased when it is combined with Enzalutamide. Eplerenone Fostamatinib may increase the antihypertensive activities of Eplerenone. Epoprostenol Fostamatinib may increase the antihypertensive activities of Epoprostenol. Eprosartan Fostamatinib may increase the antihypertensive activities of Eprosartan. Erdafitinib The metabolism of Erdafitinib can be decreased when combined with Fostamatinib. Ergotamine The metabolism of Fostamatinib can be decreased when combined with Ergotamine. Erlotinib The metabolism of Erlotinib can be decreased when combined with Fostamatinib. Ertugliflozin Fostamatinib may decrease the excretion rate of Ertugliflozin which could result in a higher serum level. Erythrityl tetranitrate The risk or severity of hypotension can be increased when Fostamatinib is combined with Erythrityl tetranitrate. Erythromycin The metabolism of Fostamatinib can be decreased when combined with Erythromycin. Eslicarbazepine The metabolism of Eslicarbazepine can be decreased when combined with Fostamatinib. Eslicarbazepine acetate The metabolism of Eslicarbazepine acetate can be decreased when combined with Fostamatinib. Esmolol Fostamatinib may increase the antihypertensive activities of Esmolol. Estetrol The metabolism of Estetrol can be decreased when combined with Fostamatinib. Estradiol The metabolism of Estradiol can be decreased when combined with Fostamatinib. Estradiol acetate The metabolism of Estradiol acetate can be decreased when combined with Fostamatinib. Estradiol benzoate The metabolism of Estradiol benzoate can be decreased when combined with Fostamatinib. Estradiol cypionate The metabolism of Estradiol cypionate can be decreased when combined with Fostamatinib. Estradiol dienanthate The metabolism of Estradiol dienanthate can be decreased when combined with Fostamatinib. Estradiol valerate The metabolism of Estradiol valerate can be decreased when combined with Fostamatinib. Eszopiclone The metabolism of Eszopiclone can be decreased when combined with Fostamatinib. Etacrynic acid The risk or severity of hypotension can be increased when Fostamatinib is combined with Etacrynic acid. Ethanol Ethanol may increase the hypotensive activities of Fostamatinib. Ethinylestradiol The metabolism of Ethinylestradiol can be decreased when combined with Fostamatinib. Etoposide The metabolism of Etoposide can be decreased when combined with Fostamatinib. Everolimus The metabolism of Everolimus can be decreased when combined with Fostamatinib. Ezetimibe Fostamatinib may decrease the excretion rate of Ezetimibe which could result in a higher serum level. Ezogabine The metabolism of Ezogabine can be decreased when combined with Fostamatinib. Febuxostat The metabolism of Febuxostat can be decreased when combined with Fostamatinib. Felodipine Fostamatinib may increase the antihypertensive activities of Felodipine. Fenofibrate The metabolism of Fenofibrate can be decreased when combined with Fostamatinib. Fenoldopam Fostamatinib may increase the antihypertensive activities of Fenoldopam. Fentanyl The metabolism of Fentanyl can be decreased when combined with Fostamatinib. Finerenone The serum concentration of Finerenone can be increased when it is combined with Fostamatinib. Fluconazole The metabolism of Fostamatinib can be decreased when combined with Fluconazole. Fluorouracil Fostamatinib may decrease the excretion rate of Fluorouracil which could result in a higher serum level. Flupentixol The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Flupentixol. Flurbiprofen The metabolism of Flurbiprofen can be decreased when combined with Fostamatinib. Fluvastatin The metabolism of Fluvastatin can be decreased when combined with Fostamatinib. Fluvoxamine The metabolism of Fostamatinib can be decreased when combined with Fluvoxamine. Folic acid Fostamatinib may decrease the excretion rate of Folic acid which could result in a higher serum level. Follitropin The therapeutic efficacy of Follitropin can be decreased when used in combination with Fostamatinib. Fosaprepitant The metabolism of Fosaprepitant can be decreased when combined with Fostamatinib. Fosinopril Fostamatinib may increase the antihypertensive activities of Fosinopril. Fosnetupitant The metabolism of Fostamatinib can be decreased when combined with Fosnetupitant. Fosphenytoin The metabolism of Fosphenytoin can be decreased when combined with Fostamatinib. Fostemsavir Fostamatinib may decrease the excretion rate of Fostemsavir which could result in a higher serum level. Fulvestrant The metabolism of Fulvestrant can be decreased when combined with Fostamatinib. Furosemide The metabolism of Furosemide can be decreased when combined with Fostamatinib. Fusidic acid The metabolism of Fostamatinib can be decreased when combined with Fusidic acid. Gefitinib Fostamatinib may decrease the excretion rate of Gefitinib which could result in a higher serum level. Gemfibrozil The metabolism of Gemfibrozil can be decreased when combined with Fostamatinib. Gilteritinib The metabolism of Gilteritinib can be decreased when combined with Fostamatinib. Glasdegib Fostamatinib may decrease the excretion rate of Glasdegib which could result in a higher serum level. Glecaprevir Fostamatinib may decrease the excretion rate of Glecaprevir which could result in a higher serum level. Glipizide The metabolism of Glipizide can be decreased when combined with Fostamatinib. Glyburide Fostamatinib may decrease the excretion rate of Glyburide which could result in a higher serum level. Guanabenz Fostamatinib may increase the antihypertensive activities of Guanabenz. Guanadrel Fostamatinib may increase the antihypertensive activities of Guanadrel. Guanethidine Fostamatinib may increase the antihypertensive activities of Guanethidine. Guanfacine Fostamatinib may increase the antihypertensive activities of Guanfacine. Guanoxan Fostamatinib may increase the antihypertensive activities of Guanoxan. Haloperidol The serum concentration of Haloperidol can be increased when it is combined with Fostamatinib. Halothane The risk or severity of hypotension can be increased when Fostamatinib is combined with Halothane. Hydralazine Fostamatinib may increase the antihypertensive activities of Hydralazine. Hydrochlorothiazide Fostamatinib may increase the antihypertensive activities of Hydrochlorothiazide. Hydroflumethiazide Fostamatinib may increase the antihypertensive activities of Hydroflumethiazide. Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Fostamatinib. Ibuprofen The metabolism of Ibuprofen can be decreased when combined with Fostamatinib. Idelalisib The metabolism of Idelalisib can be decreased when combined with Fostamatinib. Ifosfamide The metabolism of Ifosfamide can be decreased when combined with Fostamatinib. Iloperidone The metabolism of Iloperidone can be decreased when combined with Fostamatinib. Iloprost The risk or severity of hypotension can be increased when Fostamatinib is combined with Iloprost. Imatinib Fostamatinib may decrease the excretion rate of Imatinib which could result in a higher serum level. Imipramine The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Imipramine. Indacaterol The metabolism of Indacaterol can be decreased when combined with Fostamatinib. Indapamide Fostamatinib may increase the antihypertensive activities of Indapamide. Indinavir The metabolism of Fostamatinib can be decreased when combined with Indinavir. Indomethacin The metabolism of Indomethacin can be decreased when combined with Fostamatinib. Indoramin The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Indoramin. Infigratinib The metabolism of Infigratinib can be decreased when combined with Fostamatinib. Irbesartan Fostamatinib may increase the antihypertensive activities of Irbesartan. Irinotecan The risk or severity of neutropenia can be increased when Fostamatinib is combined with Irinotecan. Isavuconazole The metabolism of Fostamatinib can be decreased when combined with Isavuconazole. Isavuconazonium The metabolism of Fostamatinib can be decreased when combined with Isavuconazonium. Isocarboxazid The risk or severity of hypotension can be increased when Fostamatinib is combined with Isocarboxazid. Isoflurane The risk or severity of hypotension can be increased when Fostamatinib is combined with Isoflurane. Isoniazid The metabolism of Fostamatinib can be decreased when combined with Isoniazid. Isosorbide The risk or severity of hypotension can be increased when Fostamatinib is combined with Isosorbide. Isosorbide dinitrate The risk or severity of hypotension can be increased when Fostamatinib is combined with Isosorbide dinitrate. Isosorbide mononitrate Fostamatinib may increase the vasodilatory activities of Isosorbide mononitrate. Isoxsuprine The risk or severity of hypotension can be increased when Fostamatinib is combined with Isoxsuprine. Isradipine The metabolism of Fostamatinib can be decreased when combined with Isradipine. Itraconazole The metabolism of Fostamatinib can be decreased when combined with Itraconazole. Ivermectin Fostamatinib may decrease the excretion rate of Ivermectin which could result in a higher serum level. Ivosidenib The metabolism of Fostamatinib can be increased when combined with Ivosidenib. Ixabepilone The metabolism of Ixabepilone can be decreased when combined with Fostamatinib. Ixazomib The metabolism of Ixazomib can be decreased when combined with Fostamatinib. Ketoconazole The metabolism of Fostamatinib can be decreased when combined with Ketoconazole. Ketoprofen The metabolism of Ketoprofen can be decreased when combined with Fostamatinib. Labetalol The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Labetalol. Lacidipine Fostamatinib may increase the antihypertensive activities of Lacidipine. Lacosamide The metabolism of Lacosamide can be decreased when combined with Fostamatinib. Lamivudine Fostamatinib may decrease the excretion rate of Lamivudine which could result in a higher serum level. Lamotrigine The metabolism of Lamotrigine can be decreased when combined with Fostamatinib. Lefamulin The metabolism of Lefamulin can be decreased when combined with Fostamatinib. Leflunomide Fostamatinib may decrease the excretion rate of Leflunomide which could result in a higher serum level. Lenvatinib Fostamatinib may decrease the excretion rate of Lenvatinib which could result in a higher serum level. Lercanidipine Fostamatinib may increase the antihypertensive activities of Lercanidipine. Letermovir The metabolism of Letermovir can be decreased when combined with Fostamatinib. Levacetylmethadol The metabolism of Levacetylmethadol can be decreased when combined with Fostamatinib. Levamlodipine The serum concentration of Levamlodipine can be increased when it is combined with Fostamatinib. Levobunolol The risk or severity of hypotension can be increased when Fostamatinib is combined with Levobunolol. Levobupivacaine The risk or severity of hypotension can be increased when Fostamatinib is combined with Levobupivacaine. Levodopa The risk or severity of hypotension can be increased when Fostamatinib is combined with Levodopa. Levoketoconazole The metabolism of Fostamatinib can be decreased when combined with Levoketoconazole. Levosimendan The risk or severity of hypotension can be increased when Fostamatinib is combined with Levosimendan. Levothyroxine The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Fostamatinib. Linagliptin The metabolism of Fostamatinib can be decreased when combined with Linagliptin. Liothyronine The therapeutic efficacy of Liothyronine can be decreased when used in combination with Fostamatinib. Liotrix The therapeutic efficacy of Liotrix can be decreased when used in combination with Fostamatinib. Lisinopril Fostamatinib may increase the antihypertensive activities of Lisinopril. Lofexidine Fostamatinib may increase the antihypertensive activities of Lofexidine. Lomitapide The metabolism of Lomitapide can be decreased when combined with Fostamatinib. Lonafarnib The metabolism of Fostamatinib can be decreased when combined with Lonafarnib. Lopinavir The serum concentration of R406, an active metabolite of Fostamatinib, can be increased when used in combination with Lopinavir. Losartan The metabolism of Losartan can be decreased when combined with Fostamatinib. You Might Also Read Ivermectin Contraindications, Dosage, Side Effects Lovastatin The metabolism of Lovastatin can be decreased when combined with Fostamatinib. Lumacaftor The metabolism of Fostamatinib can be increased when combined with Lumacaftor. Lumateperone The serum concentration of Lumateperone can be increased when it is combined with Fostamatinib. Lusutrombopag Fostamatinib may decrease the excretion rate of Lusutrombopag which could result in a higher serum level. Macitentan Fostamatinib may increase the antihypertensive activities of Macitentan. Manidipine Fostamatinib may increase the antihypertensive activities of Manidipine. Mannitol The risk or severity of hypotension can be increased when Fostamatinib is combined with Mannitol. Mavacamten The serum concentration of Fostamatinib can be decreased when it is combined with Mavacamten. Mecamylamine Fostamatinib may increase the antihypertensive activities of Mecamylamine. Mefenamic acid The metabolism of Fostamatinib can be decreased when combined with Mefenamic acid. Meperidine The metabolism of Meperidine can be decreased when combined with Fostamatinib. Methazolamide The risk or severity of hypotension can be increased when Fostamatinib is combined with Methazolamide. Methimazole The metabolism of Fostamatinib can be decreased when combined with Methimazole. Methotrexate The metabolism of Methotrexate can be decreased when combined with Fostamatinib. Methotrimeprazine The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Methotrimeprazine. Methyldopa Fostamatinib may increase the antihypertensive activities of Methyldopa. Methylene blue The metabolism of Fostamatinib can be decreased when combined with Methylene blue. Methylprednisone The metabolism of Methylprednisone can be decreased when combined with Fostamatinib. Methysergide The metabolism of Methysergide can be decreased when combined with Fostamatinib. Metipranolol The risk or severity of hypotension can be increased when Fostamatinib is combined with Metipranolol. Metolazone Fostamatinib may increase the antihypertensive activities of Metolazone. Metoprolol Fostamatinib may increase the antihypertensive activities of Metoprolol. Metreleptin The metabolism of Fostamatinib can be increased when combined with Metreleptin. Metronidazole The metabolism of Metronidazole can be decreased when combined with Fostamatinib. Metyrosine Fostamatinib may increase the antihypertensive activities of Metyrosine. Miconazole The metabolism of Fostamatinib can be decreased when combined with Miconazole. Midazolam The serum concentration of Midazolam can be increased when it is combined with Fostamatinib. Midostaurin The metabolism of Fostamatinib can be decreased when combined with Midostaurin. Migalastat The metabolism of Migalastat can be decreased when combined with Fostamatinib. Milnacipran The metabolism of Fostamatinib can be decreased when combined with Milnacipran. Minoxidil The metabolism of Minoxidil can be decreased when combined with Fostamatinib. Mitotane The metabolism of Fostamatinib can be increased when combined with Mitotane. Mitoxantrone Fostamatinib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level. Moexipril Fostamatinib may increase the antihypertensive activities of Moexipril. Molsidomine Molsidomine may increase the hypotensive activities of Fostamatinib. Morphine The metabolism of Morphine can be decreased when combined with Fostamatinib. Moxonidine Fostamatinib may increase the antihypertensive activities of Moxonidine. Muzolimine Fostamatinib may increase the antihypertensive activities of Muzolimine. Mycophenolate mofe Fostamatinib may decrease the excretion rate of Mycophenolate mofetil which could result in a higher serum level. Mycophenolic acid The metabolism of Mycophenolic acid can be decreased when combined with Fostamatinib. Nabilone The risk or severity of hypotension can be increased when Fostamatinib is combined with Nabilone. Nadolol Fostamatinib may increase the antihypertensive activities of Nadolol. Naloxone The metabolism of Fostamatinib can be decreased when combined with Naloxone. Naltrexone The metabolism of Naltrexone can be decreased when combined with Fostamatinib. Naproxen The metabolism of Naproxen can be decreased when combined with Fostamatinib. Nebivolol Fostamatinib may increase the antihypertensive activities of Nebivolol. Nefazodone The metabolism of Fostamatinib can be decreased when combined with Nefazodone. Nelfinavir The metabolism of Fostamatinib can be decreased when combined with Nelfinavir. Neratinib The metabolism of Neratinib can be decreased when combined with Fostamatinib. Nesiritide The risk or severity of hypotension can be increased when Fostamatinib is combined with Nesiritide. Netupitant The metabolism of Fostamatinib can be decreased when combined with Netupitant. Nicardipine The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Nicardipine. Nicergoline The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Nicergoline. Nicorandil Fostamatinib may increase the hypotensive activities of Nicorandil. Nifedipine The risk or severity of hypotension can be increased when Fostamatinib is combined with Nifedipine. Nilotinib The metabolism of Fostamatinib can be decreased when combined with Nilotinib. Nilvadipine The metabolism of Fostamatinib can be decreased when combined with Nilvadipine. Nimodipine Fostamatinib may increase the antihypertensive activities of Nimodipine. Nintedanib The metabolism of Nintedanib can be decreased when combined with Fostamatinib. Nisoldipine Fostamatinib may increase the antihypertensive activities of Nisoldipine. Nitrendipine Fostamatinib may increase the antihypertensive activities of Nitrendipine. Nitric Oxide The risk or severity of hypotension can be increased when Fostamatinib is combined with Nitric Oxide. Nitrofurantoin Fostamatinib may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level. Nitroglycerin The risk or severity of hypotension can be increased when Fostamatinib is combined with Nitroglycerin. Nitroprusside Fostamatinib may increase the antihypertensive activities of Nitroprusside. Nitrous acid The risk or severity of hypotension can be increased when Fostamatinib is combined with Nitrous acid. Norethisterone The metabolism of Norethisterone can be decreased when combined with Fostamatinib. Norgestimate The metabolism of Norgestimate can be decreased when combined with Fostamatinib. Nortriptyline The metabolism of Nortriptyline can be decreased when combined with Fostamatinib. Obinutuzumab The risk or severity of hypotension can be increased when Fostamatinib is combined with Obinutuzumab. Olanzapine The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Olanzapine. Olaparib The metabolism of Olaparib can be decreased when combined with Fostamatinib. Olmesartan Fostamatinib may increase the antihypertensive activities of Olmesartan. Ombitasvir Fostamatinib may decrease the excretion rate of Ombitasvir which could result in a higher serum level. Opicapone The risk or severity of hypotension can be increased when Fostamatinib is combined with Opicapone. Osimertinib The metabolism of Osimertinib can be decreased when combined with Fostamatinib. Oxaliplatin Fostamatinib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Oxprenolol Fostamatinib may increase the antihypertensive activities of Oxprenolol. Ozanimod Fostamatinib may decrease the excretion rate of Ozanimod which could result in a higher serum level. Paclitaxel The metabolism of Paclitaxel can be decreased when combined with Fostamatinib. Palbociclib The metabolism of Palbociclib can be decreased when combined with Fostamatinib. Paliperidone The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Paliperidone. Panobinostat The metabolism of Panobinostat can be decreased when combined with Fostamatinib. Papaverine The risk or severity of hypotension can be increased when Fostamatinib is combined with Papaverine. Parathyroid hormone The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Fostamatinib. Pargyline Fostamatinib may increase the antihypertensive activities of Pargyline. Patent Blue The therapeutic efficacy of Fostamatinib can be decreased when used in combination with Patent Blue. Pazopanib The metabolism of Pazopanib can be decreased when combined with Fostamatinib. Penbutolol Fostamatinib may increase the antihypertensive activities of Penbutolol. Pentaerythritol The risk or severity of hypotension can be increased when Fostamatinib is combined with Pentaerythritol tetranitrate. Pentobarbital The metabolism of Fostamatinib can be increased when combined with Pentobarbital. Pentolinium Fostamatinib may increase the antihypertensive activities of Pentolinium. Periciazine The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Periciazine. Perindopril Fostamatinib may increase the antihypertensive activities of Perindopril. Pexidartinib The metabolism of Pexidartinib can be decreased when combined with Fostamatinib. Phenelzine The risk or severity of hypotension can be increased when Fostamatinib is combined with Phenelzine. Phenobarbital The metabolism of Fostamatinib can be increased when combined with Phenobarbital. Phenoxybenzamine The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Phenoxybenzamine. Phenprocoumon The metabolism of Phenprocoumon can be decreased when combined with Fostamatinib. Phentolamine The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Phentolamine. Phenylephrine The risk or severity of hypertension can be decreased when Fostamatinib is combined with Phenylephrine. Phenytoin The metabolism of Fostamatinib can be increased when combined with Phenytoin. Pibrentasvir Fostamatinib may decrease the excretion rate of Pibrentasvir which could result in a higher serum level. Pimavanserin The metabolism of Pimavanserin can be decreased when combined with Fostamatinib. Pimozide The metabolism of Pimozide can be decreased when combined with Fostamatinib. Pinacidil Fostamatinib may increase the antihypertensive activities of Pinacidil. Pindolol Fostamatinib may increase the antihypertensive activities of Pindolol. Pitavastatin Fostamatinib may decrease the excretion rate of Pitavastatin which could result in a higher serum level. Pitolisant The serum concentration of Fostamatinib can be decreased when it is combined with Pitolisant. Pizotifen The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Pizotifen. Polythiazide Fostamatinib may increase the antihypertensive activities of Polythiazide. Pomalidomide The metabolism of Pomalidomide can be decreased when combined with Fostamatinib. Ponatinib The metabolism of Ponatinib can be decreased when combined with Fostamatinib. Ponesimod The metabolism of Ponesimod can be decreased when combined with Fostamatinib. Posaconazole The metabolism of Fostamatinib can be decreased when combined with Posaconazole. Potassium Iodide The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Fostamatinib. Potassium perchlorate The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Fostamatinib. Practolol Fostamatinib may increase the antihypertensive activities of Practolol. Pralatrexate Fostamatinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Pralsetinib Fostamatinib may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Pramipexole The risk or severity of hypotension can be increased when Fostamatinib is combined with Pramipexole. Pravastatin Fostamatinib may decrease the excretion rate of Pravastatin which could result in a higher serum level. Prazosin The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Prazosin. Pretomanid The metabolism of Pretomanid can be decreased when combined with Fostamatinib. Primaquine The metabolism of Fostamatinib can be decreased when combined with Primaquine. Primidone The metabolism of Fostamatinib can be increased when combined with Primidone. Promazine The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Promazine. Propiomazine The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Propiomazine. Propiverine The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Propiverine. Propofol The metabolism of Propofol can be decreased when combined with Fostamatinib. Propranolol Fostamatinib may increase the antihypertensive activities of Propranolol. Propylthiouracil The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Fostamatinib. Protirelin The therapeutic efficacy of Protirelin can be decreased when used in combination with Fostamatinib. Prucalopride The metabolism of Prucalopride can be decreased when combined with Fostamatinib. Quetiapine The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Quetiapine. Quinapril Fostamatinib may increase the antihypertensive activities of Quinapril. Quinidine The metabolism of Quinidine can be decreased when combined with Fostamatinib. Raloxifene Fostamatinib may decrease the excretion rate of Raloxifene which could result in a higher serum level. Raltegravir The metabolism of Raltegravir can be decreased when combined with Fostamatinib. Ramipril Fostamatinib may increase the antihypertensive activities of Ramipril. Rasagiline The risk or severity of hypotension can be increased when Fostamatinib is combined with Rasagiline. Regorafenib The metabolism of Regorafenib can be decreased when combined with Fostamatinib. Remifentanil The risk or severity of hypotension can be increased when Fostamatinib is combined with Remifentanil. Rescinnamine Fostamatinib may increase the antihypertensive activities of Rescinnamine. Reserpine Fostamatinib may increase the antihypertensive activities of Reserpine. Retapamulin The metabolism of Retapamulin can be decreased when combined with Fostamatinib. Revefenacin Fostamatinib may decrease the excretion rate of Revefenacin which could result in a higher serum level. Ribociclib The metabolism of Fostamatinib can be decreased when combined with Ribociclib. Rifampicin The metabolism of Fostamatinib can be increased when combined with Rifampicin. Rifamycin The metabolism of Fostamatinib can be increased when combined with Rifamycin. Rifapentine The metabolism of Fostamatinib can be increased when combined with Rifapentine. Rilmenidine Fostamatinib may increase the antihypertensive activities of Rilmenidine. Riluzole Fostamatinib may decrease the excretion rate of Riluzole which could result in a higher serum level. Rimegepant The serum concentration of Rimegepant can be increased when it is combined with Fostamatinib. Riociguat Fostamatinib may increase the hypotensive activities of Riociguat. Ripretinib Fostamatinib may decrease the excretion rate of Ripretinib which could result in a higher serum level. Risperidone The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Risperidone. Ritonavir The serum concentration of R406, an active metabolite of Fostamatinib, can be increased when used in combination with Ritonavir. Rivaroxaban Fostamatinib may decrease the excretion rate of Rivaroxaban which could result in a higher serum level. Roflumilast The serum concentration of Roflumilast can be increased when it is combined with Fostamatinib. Romidepsin The metabolism of Romidepsin can be decreased when combined with Fostamatinib. Ropinirole The risk or severity of hypotension can be increased when Fostamatinib is combined with Ropinirole. Ropivacaine The risk or severity of hypotension can be increased when Fostamatinib is combined with Ropivacaine. Rosuvastatin Fostamatinib may decrease the excretion rate of Rosuvastatin which could result in a higher serum level. Rotigotine The risk or severity of hypotension can be increased when Fostamatinib is combined with Rotigotine. Rucaparib Fostamatinib may decrease the excretion rate of Rucaparib which could result in a higher serum level. Ruxolitinib The metabolism of Ruxolitinib can be decreased when combined with Fostamatinib. Sacituzumab govitecan The serum concentration of Sacituzumab govitecan can be increased when it is combined with Fostamatinib. Sacubitril The risk or severity of hypotension can be increased when Fostamatinib is combined with Sacubitril. Salmon calcitonin The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Fostamatinib. Sapropterin Sapropterin may increase the hypotensive activities of Fostamatinib. Saquinavir The metabolism of Fostamatinib can be decreased when combined with Saquinavir. Satralizumab The serum concentration of Fostamatinib can be decreased when it is combined with Satralizumab. Selegiline The risk or severity of hypotension can be increased when Fostamatinib is combined with Selegiline. Selexipag Fostamatinib may increase the antihypertensive activities of Selexipag. Selumetinib Fostamatinib may decrease the excretion rate of Selumetinib which could result in a higher serum level. Sevoflurane The risk or severity of hypotension can be increased when Fostamatinib is combined with Sevoflurane. Sildenafil The risk or severity of adverse effects can be increased when Sildenafil is combined with Fostamatinib. Silodosin The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Silodosin. Simeprevir The metabolism of Fostamatinib can be decreased when combined with Simeprevir. Simvastatin The metabolism of Simvastatin can be decreased when combined with Fostamatinib. Siponimod The metabolism of Siponimod can be decreased when combined with Fostamatinib. Sirolimus The metabolism of Sirolimus can be decreased when combined with Fostamatinib. Sitaxentan Fostamatinib may increase the antihypertensive activities of Sitaxentan. Sofosbuvir Fostamatinib may decrease the excretion rate of Sofosbuvir which could result in a higher serum level. Somatrogon The metabolism of Fostamatinib can be increased when combined with Somatrogon. Sonidegib The metabolism of Sonidegib can be decreased when combined with Fostamatinib. Sorafenib The metabolism of Sorafenib can be decreased when combined with Fostamatinib. Sotalol The risk or severity of hypotension can be increased when Fostamatinib is combined with Sotalol. Sotorasib The serum concentration of Fostamatinib can be decreased when it is combined with Sotorasib. Spirapril Fostamatinib may increase the antihypertensive activities of Spirapril. Spironolactone The risk or severity of hypotension can be increased when Fostamatinib is combined with Spironolactone. St. John’s Wort The metabolism of Fostamatinib can be increased when combined with St. John’s Wort. Stiripentol The metabolism of Fostamatinib can be decreased when combined with Stiripentol. Streptokinase The risk or severity of hypotension can be increased when Fostamatinib is combined with Streptokinase. Sufentanil The risk or severity of hypotension can be increased when Fostamatinib is combined with Sufentanil. Sulfasalazine Fostamatinib may decrease the excretion rate of Sulfasalazine which could result in a higher serum level. Sumatriptan Fostamatinib may decrease the excretion rate of Sumatriptan which could result in a higher serum level. Sunitinib The metabolism of Sunitinib can be decreased when combined with Fostamatinib. Suvorexant The metabolism of Suvorexant can be decreased when combined with Fostamatinib You Might Also Read Ranitidine, Uses, Dosage, Side Effects, Interactions, Pregnancy Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Fostamatinib. Tadalafil The risk or severity of adverse effects can be increased when Tadalafil is combined with Fostamatinib. Talazoparib Fostamatinib may decrease the excretion rate of Talazoparib which could result in a higher serum level. Tamoxifen The metabolism of Tamoxifen can be decreased when combined with Fostamatinib. Tamsulosin The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Tamsulosin. Tasimelteon The metabolism of Tasimelteon can be decreased when combined with Fostamatinib. Tazemetostat Fostamatinib may decrease the excretion rate of Tazemetostat which could result in a higher serum level. Tegaserod Fostamatinib may decrease the excretion rate of Tegaserod which could result in a higher serum level. Telaprevir The metabolism of Fostamatinib can be decreased when combined with Telaprevir. Telithromycin The metabolism of Fostamatinib can be decreased when combined with Telithromycin. Telmisartan Fostamatinib may increase the antihypertensive activities of Telmisartan. Telotristat ethyl The serum concentration of Fostamatinib can be decreased when it is combined with Telotristat ethyl. Temsirolimus The metabolism of Temsirolimus can be decreased when combined with Fostamatinib. Teniposide The metabolism of Teniposide can be decreased when combined with Fostamatinib. Tenofovir alafenamide The serum concentration of Tenofovir alafenamide can be increased when it is combined with Fostamatinib. Terazosin The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Terazosin. Terfenadine The metabolism of Fostamatinib can be decreased when combined with Terfenadine. Teriflunomide Fostamatinib may decrease the excretion rate of Teriflunomide which could result in a higher serum level. Teriparatide The therapeutic efficacy of Teriparatide can be decreased when used in combination with Fostamatinib. Testosterone Fostamatinib may decrease the excretion rate of Testosterone which could result in a higher serum level. Testosterone cypionate Fostamatinib may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level. Testosterone enanthate Fostamatinib may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level. Thalidomide The risk or severity of hypotension can be increased when Fostamatinib is combined with Thalidomide. Theophylline The metabolism of Theophylline can be decreased when combined with Fostamatinib. Thiopental The risk or severity of hypotension can be increased when Fostamatinib is combined with Thiopental. Thioridazine The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Thioridazine. Thiotepa The metabolism of Thiotepa can be decreased when combined with Fostamatinib. Thyroid, porcine The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Fostamatinib. Thyrotropin alfa The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Fostamatinib. Tiagabine The metabolism of Tiagabine can be decreased when combined with Fostamatinib. Timolol Fostamatinib may increase the antihypertensive activities of Timolol. Tipranavir The metabolism of Fostamatinib can be decreased when combined with Tipranavir. Tizanidine The risk or severity of hypotension can be increased when Fostamatinib is combined with Tizanidine. Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Fostamatinib. Tolazoline The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Tolazoline. Tolcapone The risk or severity of hypotension can be increased when Fostamatinib is combined with Tolcapone. Tolvaptan The metabolism of Tolvaptan can be decreased when combined with Fostamatinib. Topotecan Fostamatinib may decrease the excretion rate of Topotecan which could result in a higher serum level. Torasemide Fostamatinib may increase the antihypertensive activities of Torasemide. Trabectedin The metabolism of Trabectedin can be decreased when combined with Fostamatinib. Tramadol The metabolism of Tramadol can be decreased when combined with Fostamatinib. Trandolapril Fostamatinib may increase the antihypertensive activities of Trandolapril. Tranylcypromine The risk or severity of hypotension can be increased when Fostamatinib is combined with Tranylcypromine. Trastuzumab emtansine The metabolism of Trastuzumab emtansine can be decreased when combined with Fostamatinib. Trazodone The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Trazodone. Treprostinil Fostamatinib may increase the antihypertensive activities of Treprostinil. Tretinoin The risk or severity of hypotension can be increased when Fostamatinib is combined with Tretinoin. Triamterene The risk or severity of hypotension can be increased when Fostamatinib is combined with Triamterene. Trichlormethiazide Fostamatinib may increase the antihypertensive activities of Trichlormethiazide. Trifluoperazine The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Trifluoperazine. Trilaciclib Fostamatinib may decrease the excretion rate of Trilaciclib which could result in a higher serum level. Trimethaphan Fostamatinib may increase the antihypertensive activities of Trimethaphan. Trimipramine The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Trimipramine. Troglitazone The metabolism of Troglitazone can be decreased when combined with Fostamatinib. Troleandomycin The metabolism of Fostamatinib can be decreased when combined with Troleandomycin. Tucatinib The metabolism of Tucatinib can be decreased when combined with Fostamatinib. Ubrogepant The serum concentration of Ubrogepant can be increased when it is combined with Fostamatinib. Udenafil The risk or severity of adverse effects can be increased when Udenafil is combined with Fostamatinib. Valproic acid The metabolism of Valproic acid can be decreased when combined with Fostamatinib. Valsartan Fostamatinib may increase the antihypertensive activities of Valsartan. Vandetanib The metabolism of Vandetanib can be decreased when combined with Fostamatinib. Vardenafil The metabolism of Vardenafil can be decreased when combined with Fostamatinib. Velpatasvir Fostamatinib may decrease the excretion rate of Velpatasvir which could result in a higher serum level. Vemurafenib The metabolism of Vemurafenib can be decreased when combined with Fostamatinib. Venetoclax The metabolism of Venetoclax can be decreased when combined with Fostamatinib. Verapamil The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Verapamil. Vericiguat The risk or severity of hypotension can be increased when Fostamatinib is combined with Vericiguat. Viloxazine The metabolism of Fostamatinib can be decreased when combined with Viloxazine. Vinblastine The metabolism of Vinblastine can be decreased when combined with Fostamatinib. Vincristine The metabolism of Vincristine can be decreased when combined with Fostamatinib. Vindesine The metabolism of Vindesine can be decreased when combined with Fostamatinib. Vinflunine The metabolism of Vinflunine can be decreased when combined with Fostamatinib. Vinorelbine The metabolism of Vinorelbine can be decreased when combined with Fostamatinib. Vorapaxar The metabolism of Vorapaxar can be decreased when combined with Fostamatinib. Voriconazole The serum concentration of Fostamatinib can be increased when it is combined with Voriconazole. Voxelotor The serum concentration of Voxelotor can be increased when it is combined with Fostamatinib. Voxilaprevir Fostamatinib may decrease the excretion rate of Voxilaprevir which could result in a higher serum level. Warfarin The serum concentration of Warfarin can be increased when it is combined with Fostamatinib. Zanubrutinib The metabolism of Zanubrutinib can be decreased when combined with Fostamatinib. Zidovudine Fostamatinib may decrease the excretion rate of Zidovudine which could result in a higher serum level. Zimelidine The metabolism of Fostamatinib can be decreased when combined with Zimelidine. Ziprasidone The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Ziprasidone. Zofenopril Fostamatinib may increase the antihypertensive activities of Zofenopril. Zonisamide The metabolism of Zonisamide can be decreased when combined with Fostamatinib. Zopiclone The metabolism of Zopiclone can be decreased when combined with Fostamatinib. Zuclopenthixol The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Zuclopenthixol. Pregnancy and Lactation US FDA pregnancy category: Not assigned. Pregnancy Based on findings from animal studies and the mechanism of action, this drug can cause fetal harm when administered to a pregnant woman. Adequate methods of contraception should be encouraged. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus. Lactation Use is not recommended. Excreted into human milk: Data not available Excreted into animal milk: Yes The effects on the nursing infant are unknown. The manufacturer recommends that women do not breastfeed during therapy and for at least 1 month after the last dose. How should this medicine be used? Fostamatinib comes as a tablet to take by mouth. It is usually taken with or without food twice daily. Take fostamatinib at around the same time(s) every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take fostamatinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Your doctor may need to reduce, interrupt, or discontinue your treatment if you experience certain side effects or depending on your treatment response. If your number of platelets (platelet count) does not increase to a certain level after 12 weeks of treatment, your doctor may have to discontinue your treatment. Talk to your doctor about how you are feeling during your treatment. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient. What special precautions should I follow? Before taking fostamatinib, tell your doctor and pharmacist if you are allergic to fostamatinib, any other medications, or any of the ingredients in fostamatinib tablets. Ask your pharmacist for a list of the ingredients. tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: clarithromycin (Biaxin, in Prevpac), digoxin (Lanoxin), itraconazole (Onmel, Sporanox), ketoconazole, rifampin (Rifadin, Rimactane, in Rifamate, in Rifater), and rosuvastatin (Crestor). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with fostamatinib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list. tell your doctor if you have or have ever had high blood pressure or liver disease. tell your doctor if you are pregnant or plan to become pregnant. You will need to have a pregnancy test before you start treatment, and you should use birth control to prevent pregnancy during your fostamatinib treatment and for at least 1 month after your final dose. Talk to your doctor about birth control methods that you can use. If you become pregnant, call your doctor immediately. Fostamatinib may harm the fetus. tell your doctor if you are breastfeeding. You should not breastfeed during your treatment with fostamatinib and for at least 1 month after your final dose. References https://pubchem.ncbi.nlm.nih.gov/compound/Fostamatinib https://pubchem.ncbi.nlm.nih.gov/compound/Fostamatinib-disodium https://www.cancer.gov/about-cancer/treatment/drugs/fostamatinibdisodium https://go.drugbank.com/drugs/DB12010 https://medlineplus.gov/druginfo/meds/a618025.html https://www.drugs.com/mtm/fostamatinib.html https://en.wikipedia.org/wiki/Fostamatinib https://www.webmd.com/drugs/2/drug-175199/fostamatinib-oral/details/list-contraindications https://www.mayoclinic.org/drugs-supplements/fostamatinib-disodium-oral-route/side-effects/drg-20425918 CAS Common Chemistry https://creativecommons.org/licenses/by-nc/4.0/ Fostamatinib https://commonchemistry.cas.org/detail?cas_rn=901119-35-5 ChemIDplus LICENSE https://www.nlm.nih.gov/copyright.html https://chem.nlm.nih.gov/chemidplus/sid/0901119355 ChemIDplus Chemical Information Classification https://chem.nlm.nih.gov/chemidplus/ DrugBank https://www.drugbank.ca/legal/terms_of_use Fostamatinib https://www.drugbank.ca/drugs/DB12010 EPA DSSTox LICENSE https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources Fostamatinib https://comptox.epa.gov/dashboard/DTXSID401009170 https://comptox.epa.gov/dashboard/chemical-lists/ FDA Global Substance Registration System (GSRS) https://www.fda.gov/about-fda/about-website/website-policies#linking FOSTAMATINIB https://gsrs.ncats.nih.gov/ginas/app/beta/substances/SQ8A3S5101 ChEMBL http://www.ebi.ac.uk/Information/termsofuse.html https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2103830/ ChEMBL Protein Target Tree https://www.ebi.ac.uk/chembl/g/#browse/targets Drug Gene Interaction database (DGIdb) http://www.dgidb.org/downloads FOSTAMATINIB https://www.dgidb.org/drugs/FOSTAMATINIB Therapeutic Target Database (TTD) Fostamatinib http://idrblab.net/ttd/data/drug/details/D0V8HJ ClinicalTrials.gov https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use https://clinicaltrials.gov/ LiverTox LICENSE https://www.nlm.nih.gov/copyright.html Fostamatinib https://www.ncbi.nlm.nih.gov/books/n/livertox/Fostamatinib/ NCI Thesaurus (NCIt) https://www.cancer.gov/policies/copyright-reuse https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C95222 NCI Thesaurus Tree https://ncit.nci.nih.gov European Medicines Agency (EMA) https://www.ema.europa.eu/en/about-us/legal-notice Tavlesse (EMEA/H/C/005012) https://www.ema.europa.eu/en/medicines/human/EPAR/tavlesse Fostamatinib (P/0195/2018) https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001196-pip02-17 Fostamatinib (P/0242/2012) https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001196-pip01-11 EU Clinical Trials Register https://www.clinicaltrialsregister.eu/ European Chemicals Agency (ECHA) https://echa.europa.eu/web/guest/legal-notice https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/97241 FDA Orange Book https://www.fda.gov/about-fda/about-website/website-policies#linking https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book WHO Anatomical Therapeutic Chemical (ATC) Classification https://www.whocc.no/copyright_disclaimer/ https://www.whocc.no/atc/ ATC Code https://www.whocc.no/atc_ddd_index/ Human Metabolome Database (HMDB) http://www.hmdb.ca/citing Fostamatinib http://www.hmdb.ca/metabolites/HMDB0252469 National Drug Code (NDC) Directory https://www.fda.gov/about-fda/about-website/website-policies#linking FOSTAMATINIB https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory NIPH Clinical Trials Search of Japan https://rctportal.niph.go.jp/en/ NLM RxNorm Terminology https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html fostamatinib https://rxnav.nlm.nih.gov/id/rxnorm/2044896 Protein Data Bank in Europe (PDBe) http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/2RC PubChem https://pubchem.ncbi.nlm.nih.gov PFAS and Fluorinated Compounds in PubChem https://gitlab.lcsb.uni.lu/eci/pubchem-docs/-/raw/main/pfas-tree/PFAS_Tree.pdf?inline=false RCSB Protein Data Bank (RCSB PDB) https://www.rcsb.org/pages/policies https://www.rcsb.org/ Wikidata https://creativecommons.org/publicdomain/zero/1.0/ Fostamatinib https://www.wikidata.org/wiki/Q5473550 Medical Subject Headings (MeSH) https://www.nlm.nih.gov/copyright.html fostamatinib https://www.ncbi.nlm.nih.gov/mesh/67523665 MeSH Tree http://www.nlm.nih.gov/mesh/meshhome.html KEGG https://www.kegg.jp/kegg/legal.html USP drug classification http://www.genome.jp/kegg-bin/get_htext?br08302.keg Anatomical Therapeutic Chemical (ATC) classification http://www.genome.jp/kegg-bin/get_htext?br08303.keg Target-based classification of drugs http://www.genome.jp/kegg-bin/get_htext?br08310.keg UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS) GHS Classification Tree http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html NORMAN Suspect List Exchange https://creativecommons.org/licenses/by/4.0/ NORMAN Suspect List Exchange Classification https://www.norman-network.com/nds/SLE/ PATENTSCOPE (WIPO) SID 390891458 https://pubchem.ncbi.nlm.nih.gov/substance/390891458 Show More